216
Participants
Start Date
December 14, 2020
Primary Completion Date
December 4, 2021
Study Completion Date
December 13, 2021
Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3
Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5
Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5
Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3
Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
Cliantha Research, Mississauga
MEDA Pharma GmbH & Co. KG
INDUSTRY